2016

Genome-wide significant loci for addiction and anxiety

Karen Hodgson

Laura Almasy  
*The University of Texas Rio Grande Valley*

Emma Knowles

Jack W. Kent Jr.

Joanne E. Curran  
*The University of Texas Rio Grande Valley*

See next page for additional authors

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub

Part of the Communication Sciences and Disorders Commons

**Recommended Citation**

https://scholarworks.utrgv.edu/som_pub/125

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.
Genome-wide significant loci for addiction and anxiety


Department of psychiatry, Yale University, School of Medicine, New Haven, CT, USA
South Texas Diabetes and Obesity Institute, University of Texas, Rio Grande Valley School of Medicine, Brownsville, TX, USA
Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA
Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA
Research Imaging Institute, University of Texas Health Science Center, San Antonio, TX, USA
South Texas Veterans Health System, 7400, Merton Minter, San Antonio, TX, USA
Olin Neuropsychiatric Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA
Department of Neurobiology, Yale University School of Medicine, New Haven, CT, USA
Clinical Neuroscience Division, VA National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT, USA
Psychiatry Services, Yale-New Haven Hospital, New Haven, CT, USA

Abstract

Background—Psychiatric comorbidity is common among individuals with addictive disorders, with patients frequently suffering from anxiety disorders. While the genetic architecture of comorbid addictive and anxiety disorders remains unclear, elucidating the genes involved could provide important insights into the underlying etiology.

Methods—Here we examine a sample of 1284 Mexican-Americans from randomly selected extended pedigrees. Variance decomposition methods were used to examine the role of genetics in addiction phenotypes (lifetime history of alcohol dependence, drug dependence or chronic smoking) and various forms of clinically relevant anxiety. Genome-wide univariate and bivariate linkage scans were conducted to localize the chromosomal regions influencing these traits.

Results—Addiction phenotypes and anxiety were shown to be heritable and univariate genome-wide linkage scans revealed significant quantitative trait loci for drug dependence (14q13.2–q21.2, LOD = 3.322) and a broad anxiety phenotype (12q24.32–q24.33, LOD = 2.918). Significant positive genetic correlations were observed between anxiety and each of the addiction subtypes...
(ρ_g = 0.550–0.655) and further investigation with bivariate linkage analyses identified significant pleiotropic signals for alcohol dependence-anxiety (9q33.1–q33.2, LOD = 3.054) and drug dependence-anxiety (18p11.23–p11.22, LOD = 3.425).

Conclusions—This study confirms the shared genetic underpinnings of addiction and anxiety and identifies genomic loci involved in the etiology of these comorbid disorders. The linkage signal for anxiety on 12q24 spans the location of TMEM132D, an emerging gene of interest from previous GWAS of anxiety traits, whilst the bivariate linkage signal identified for anxiety-alcohol on 9q33 peak coincides with a region where rare CNVs have been associated with psychiatric disorders. Other signals identified implicate novel regions of the genome in addiction genetics.

Keywords
Addiction; Anxiety; Comorbidity; Pleiotropy

1. Introduction

Amongst individuals addicted to licit and illicit substances, the prevalence of comorbid psychiatric illnesses is high. In particular, epidemiological evidence for the pattern of comorbidity between addiction and anxiety is well established [1]; in addicted populations, there is a significant increase in the risk for anxiety disorders, even when covarying for demographic characteristics and other psychiatric diagnoses [2,3]. For example, among individuals with alcohol dependence the risk of panic disorder and posttraumatic stress disorder are doubled and that for generalized anxiety disorder is four times the population risk [4]. As the severity of substance misuse increases, so does the observed rate of anxiety comorbidity [2,5]. Psychiatric comorbidities are also associated with poorer outcomes among individuals with addictive disorders, including more severe symptomatology, greater social and functional impairments and increased suicide risk [6]. The lifetime prevalence of anxiety disorders and substance disorders are estimated at 18.1% and 14.6%, respectively [7], making the impact of this elevated risk substantial. However, the directionality of these effects is not clear. Increased comorbidity could be conceptualized as addiction increasing the likelihood of anxiety (due to drug use or withdrawal [8]), anxiety increasing the likelihood of addiction (to self-medicate symptoms [9]), or a third factor increasing the risk of both addiction and anxiety [5]. Disentangling these influences is highly complex, but as a potential starting point to unpick this relationship, twin and family studies focusing on alcohol disorders suggest that there may be a shared genetic etiology influencing liability to both addiction and anxiety [5,10,11].

Genetics play an important role in addiction disorders [12]. Heritability estimate for addiction to specific drugs are well established [13]. Furthermore, twin and family studies indicate that in addition to substance-specific genetic influences, there are common genetic factors acting across addiction phenotypes [14–16]. These findings suggest that genetic liability to addictive disorders arises from an increased propensity to addiction in general, combined with influences that are specific to that particular drug. Similarly, anxiety disorders are interlinked with one another, with high comorbidity rates (one study estimates 76% of anxiety cases have a experienced at least one other anxiety or depressive disorder [17]). We know that anxiety disorders are heritable [18,19], and as with addiction
phenotypes, multivariate analyses exploring the genetic relationship between the different anxiety disorders have been undertaken. Results indicate an important role for common genetic influences acting across anxiety subtypes in addition to subtype-specific genetic influences [20–22]. Indeed, Tambs et al. [20] report that heritability estimates for liability to any anxiety disorder (including PTSD and OCD) are higher than those for individual anxiety subtypes. Furthermore, the common genetic influences acting across anxiety subtypes substantially (but not completely) overlap with the genetic factors associated with neuroticism [23].

The high comorbidity between addictive and anxious phenotypes may reflect shared genetic influences. Genetics factors contribute substantially to the phenotypic correlations between alcohol consumption and anxiety or depression symptoms in twins [11]. Furthermore, a number of studies looking at patterns of transmission in families show shared familial risk factors for alcohol dependence and panic disorder [5,10], consistent with the hypothesis that addiction and anxiety are genetically correlated traits. Nevertheless, these studies have tended to focus on alcohol-related phenotypes; there is less work considering whether this genetic overlap generalizes across addiction subtypes.

To gain insight into the neurobiology underlying the overlap between addiction and anxiety, it is important to both understand the extent to which genetic liabilities are common among traits, and identify the genetic loci that contribute to this shared liability. Linkage analysis within family studies can allow us to do this by identifying chromosomal regions that segregate in families with disease. Furthermore, linkage methods capture a diverse range of types of genetic effects, including common and rare variants that are also important contributors to the risk for psychiatric disorders [24,25]. A number of univariate genome-wide linkage efforts have been published exploring anxiety disorders [26], and addiction [27–29]. While some genes implicated in this comorbidity have been linked separately to the risk for each disorder using candidate approaches, including neuropeptide Y [30,31] and GABA [32], we are unaware of any previous studies that have used linkage methods to investigate the comorbidity of these disorders on a genome-wide scale. Here, we employ bivariate linkage approaches looking at addiction and anxiety traits together, to identify chromosomal regions with pleiotropic influences on both traits. Bivariate linkage analysis provides greater statistical power to detect quantitative trait loci for correlated traits, as well as improved localization of the linkage signal [33], offering a powerful tool to identify genomic regions that jointly influence these comorbid disorders. We examine the genetic influences on addiction and anxiety phenotypes using a large randomly ascertained family sample and use both univariate and bivariate linkage analyses to identify chromosomal loci that underpin these phenotypes and their patterns of comorbidity.

2. Methods

2.1. Study sample

The sample consisted of 1284 Mexican-Americans from 75 extended pedigrees (containing 2–132 subjects, mean pedigree size = 16.36, SD = 19.41) and an additional 57 genetically unrelated spouses. The mean age of the sample was 46.08 years (SD = 14.89, range = 18–97
years), and 62.7% of the sample was female. Stated pedigree relationships were confirmed using PREST and available autosomal markers [34].

The sample is a subset of the San Antonio Family Study cohort of individuals randomly ascertained with the constraints that participants must live within the San Antonio region, be Mexican-American in ancestry, and part of a large family (at least 6 1st degree relatives). Full recruitment details are available elsewhere [35,36]. All subjects provided informed written consent (as approved by Institutional Review Boards at the university of Texas, health science center San Antonio and Yale university) and the cohort have been actively participating in research for over 18 years.

2.2. Phenotypic assessment

The semi-structured Mini International Psychiatric Interview Plus (MINI-Plus; [37]) was administered to all participants, with additional questions to establish lifetime history of psychiatric disorders, using DSM-IV criteria [38]. Lifetime history of chronic smoking was defined as ever having smoked cigarettes, cigars or a pipe every day for a month or more. Lifetime history of alcohol dependence was assessed, as was drug dependence (here defined as dependence on any drugs other than tobacco or alcohol; the Supplementary materials includes the prompts given). Anxiety cases were defined as those patients meeting criteria for any of the following: panic disorder, agoraphobia, social phobia, specific phobia, OCD, PTSD, or generalized anxiety disorder. Prevalence by subtype is included in the Supplementary materials. All interviewers administering the MINI-Plus had a doctorate or master’s degree in a mental health field or a bachelor’s degree with at least 2 years of relevant experience, and high levels of diagnostic reliability were reached for anxiety and addiction disorders ($\kappa > 0.90$).

2.3. Genotyping

Genotyping for approximately one million SNPs was performed using Illumina HumanHap550v3, HumanExon510Sv1, Human1Mv1 and Human1M-Duov3 BeadChips, and following the Illumina Infinium protocol. For quality control, SNPs and samples were removed if < 95% of genotypes were present or if the minor allele was present in less than 10 individuals. Allele frequencies were calculated using maximum likelihood methods to account for pedigree relationships [39] and SNPs were observed to be in Hardy Weinberg Equilibrium. SimWalk2 was used to check for Mendelian consistency and missing genotypes were imputed (utilizing the available pedigree information) within MERLIN [40].

For linkage analysis, a subset of 28,387 SNPs from the 1 M GWAS SNPs were selected using genotypes from 345 founders. SNPs were selected on each chromosome with a minimum spacing of 1 KB and a minor allele frequency > 5%. To limit linkage disequilibrium between SNPs, a limit of pairwise $r^2 < 0.0225$ within a 100 kb sliding window was used. The selected subset of SNPs gave an average of 7–8 SNPs percentimorgan (cM). Using these 28,387 SNPs, multipoint identity-by-descent matrices were constructed at each centimorgan location, using a stochastic Markov Chain Monte Carlo procedure within LOKI [41].
2.4. Statistical analysis

SOLAR was used for all genetic analyses [42]. This software uses maximum likelihood decomposition methods to model the patterns of trait covariance between family members as a function of genetic relationships, and so estimate the genetic and environmental contributions to phenotypes within a family structure. All analyses included the covariates of age, age$^2$, sex and their interactions.

To identify the relative contribution of additive genetic and environmental influences for addiction-related and anxiety traits, univariate variance decomposition was performed, yielding trait heritability estimates. For each trait showing significant heritability, we performed genome-wide multipoint linkage analysis, to identify chromosomal loci involved in the trait of interest. Based on a method derived by Feingold et al. [43], it was previously established in this sample that a LOD score greater than 2.9 indicates a genome-wide significant linkage peak, whilst a LOD score over 1.67 is indicative of a suggestive peak (likely to occur by chance less than once per genome-wide scan) [44]. These LOD scores are per genome-wide scan, whilst here, we examined four correlated phenotypes (alcohol dependence, drug dependence, smoking and anxiety). Therefore, using the method outlined by Cheverud [45] to assess the genetic correlations between traits, we established that the effective number of traits considered was 2.61.

We then explored the genetic relationships between addiction and anxiety. First, we examined the covariance between each of the three addiction-related traits and anxiety, to obtain bivariate genetic correlations. Then, for pairs of traits where significant genetic correlations were observed, bivariate linkage analysis was performed [33]. To enable comparison with the univariate results, bivariate LOD scores were converted to a one degree-of-freedom equivalent (based upon the $P$-value for the two degrees-of-freedom test of linkage to both traits versus linkage to neither). In order to assess whether bivariate linkage signals were truly bivariate in nature, nested models were compared to test whether the model could be explained in the absence of any shared genetic effect; that is where co-occurrence of linkage peaks in the two traits occurred by chance [46]. A confidence interval of maximum LOD score $\pm 1$ was defined surrounding each significant linkage peak.

To follow up any significant linkage signals, we extracted SNPs that were located within each significant peak from the full 1 M GWAS SNPs. Using the measured genotype association (mga) method, where models include the fixed effect of the SNP and random effects of local and polygenic heritability, individual SNPs were associated traits of interest. An additive genetic model was assumed, and the first four principal components of the GWAS data were included as covariates to account for population and admixture substructure within pedigrees [47]. To test for significance, a likelihood ratio test was employed, comparing models where the genotype parameter is allowed to vary freely or is fixed to zero. Given linkage disequilibrium, the pairwise correlations between SNPs were used to calculate the effective number of independent tests within each region [48], for an appropriate multiple-testing correction.
3. Results

3.1. Univariate analyses

The prevalence and heritability of each trait is shown in Table 1. As expected, for addiction phenotypes, there are fewer female than male cases, but the majority of anxiety cases are female. When calculating the heritability of each trait, sex was a significant covariate for all phenotypes (details are given in the Supplementary materials).

Univariate genome-wide linkage scans were performed for each of the four phenotypes under consideration. Significant linkage peaks were observed for drug dependence on chromosome 14 at 41cM (LOD score = 3.322) and for anxiety on chromosome 12 at 164cM (LOD = 2.918). For alcohol dependence and smoking, genome-wide significance was not reached. The maximum linkage for alcohol dependence was on chromosome 16 at 54cM (LOD score = 2.752) and for smoking on chromosome 4 at 80cM (LOD score = 2.735). The maximum peak for every trait is shown in Fig. 1. The Supplementary materials includes details on the genes located within each of these peaks, as well as plots of genome-wide linkage results for all four traits. The linkage signal for anxiety on chromosome 12 encompasses *TMEM132D*, which has previously been associated with anxiety-related traits [49–53]. Each of the univariate linkage signals is specific to the trait of interest; LOD scores are below 0.7 for all other traits in each of the identified chromosomal loci.

3.2. Bivariate analyses

The patterns of comorbidity between addiction subtypes and anxiety are shown in Table 2 (comorbidity rates amongst the addiction subtypes are in the Supplementary materials). Patterns of shared genetic underpinnings are evident (Table 3) with significant positive genetic correlations observed between anxiety and each of the addiction traits.

Bivariate linkage scans were performed for anxiety with each of the addiction traits. Evidence of pleiotropic genomic regions were observed in two cases. For alcohol dependence and anxiety, a significant bivariate peak was observed on chromosome 9 (at 133cM, LOD = 3.054). At this location, the univariate linkage analyses gave a LOD = 2.562 for alcohol dependence and LOD = 1.673 for anxiety. Using nested models to compare coincident with pleiotropic models, this peak was observed to be pleiotropic ($\chi^2[1] = 11.38$, $p = 3.71 \times 10^{-4}$). A second significant bivariate linkage peak was observed for drug dependence and anxiety on chromosome 18 at 29 cm (LOD = 3.425, pleiotropy test $\chi^2[1] = 16.02$, $p = 3.14 \times 10^{-5}$). The univariate linkage signals at this locus were LOD = 1.098 for drug dependence and LOD = 1.887 for anxiety. No significant bivariate linkage was observed for anxiety and smoking. The significant bivariate linkage peaks are shown in Fig. 2. Genes located within these peaks and plots of the full genome-wide linkage results are in the Supplementary materials.

3.3. Association analysis of significant linkage peaks

We performed mga analysis using all of the available SNPs underneath each of the four significant linkage peaks identified. No SNPs reached peak-wide significance, for any of the four regions considered, although the most significant SNP for anxiety (rs10744424) is
4. Discussion

4.1. Summary of findings

We have demonstrated that shared genetic influences play an important role in the high rates of comorbidity between anxiety and addiction (examining alcohol dependence, drug dependence and chronic smoking in turn). We observed genetic correlations between 0.550–0.655 within a Mexican-American extended pedigree sample. This is consistent with previous findings for anxiety and alcohol dependence [5,10,11] and our genetic correlation estimates are also similar to those observed when considering addiction in relation to major depression [54,55].

Having established a common genetic etiology, we used genome-wide linkage analyses to identify specific and pleiotropic quantitative trait loci for these phenotypes. Genome-wide significant univariate linkage signals were observed for drug dependence at 14q13.2–q21.2 and for anxiety at 12q24.32–q24.33. Genomewide significant bivariate linkage peaks were observed for alcohol dependence-anxiety at 9q33.1–q33.2 and for drug dependence-anxiety at 18p11.23–p11.22. For each of the phenotypes considered here, the identified quantitative trait loci were phenotype specific; LOD scores were low (< 0.7) in the univariate linkage scans of the other traits, despite the high genetic correlations among traits. It suggests that these loci are phenotype-specific, without pleiotropic effects on the other traits studied. However, given the limited power to detect loci of small effect, it is also possible that the loci were detected only through the phenotype on which they exert the largest effect and potential pleiotropic effects on the other phenotypes cannot be excluded. We used mga analyses to try to localize these linkage signals, using available SNP data. We were unable to identify any peak-wide significant SNP associations; this may be as we were only able to examine common SNPs or possibly due to sample size limitations.

4.2. Previously implicated genomic locations

The significant linkage signals identified in this analysis show some interesting convergence with previous findings in psychiatric genetics. First, in the univariate analysis of anxiety, we observed a significant linkage peak on chromosome 12q24.32–q24.33. While this peak only just reaches the threshold for genome-wide significance, it is of particular interest given that TMEM132D (transmembrane protein 132D) lies within this region. This gene was first implicated through GWAS investigation of panic disorder, with mouse model evidence supporting an involvement in anxious behavior [49]. Since then, both common and rare variants within the gene have been associated with anxiety disorders [50–52] and links have also been observed between variants in this gene, amygdala volume and anxiety traits in healthy controls [53]. Using association analysis in this region, the best performing SNP in our sample is rs10744424 (intronic within TMEM132D), although it does not reach significance when correcting for all SNPs available in the 2.66MB linkage region. Therefore, the identification here of a linkage peak for anxiety in the same genomic region as previous research is consistent with the role of the gene in liability to anxiety disorders,
but as we are unable to more specifically localize the signal within this peak, our findings are not conclusive.

Second, we localize a bivariate linkage signal between alcohol dependence and anxiety at 9q33.1–q33.2. Previous work has linked rare CNVs within 9q33 to a number of traits, including neurodevelopmental delays and psychiatric disorders including anxiety [56]. There has also been some evidence of linkage in this region with addiction traits; in a study of alcohol-related traits a suggestive linkage peak was observed in the same location [57] and in a 2008 review of genome-wide linkage studies in smoking, this region had been implicated in four independent samples [58], although this signal was not observed in a later meta-analysis [27] and the signal has not been localized to a specific gene. Therefore, there is some tentative evidence that this genomic region may be linked to liability to a number of psychiatric traits.

The remaining linkage peaks (for drug dependence on chromosome 14 and for drug dependence-anxiety on chromosome 18) identified in this study appear to be in regions that have not previously been highlighted in addiction genetics. Generally, for illicit drugs, the genetic loci involved are not well established, which may in part be due to the difficulties in obtaining sufficiently large samples of drug dependent individuals for adequately powered genetic studies. Indeed, the drug dependent group contains individuals that are addicted to a range of different illicit drugs (such as cannabis, cocaine or tranquilizers). By grouping these individuals into a single category, we are able to increase statistical power to detect genetic effects that are common among these illicit drugs and detect both univariate and pleiotropic linkage signals, although drug-specific signals may be obscured.

It is of note that we did not observe genome-wide linkage signals within either univariate or bivariate models for smoking within this sample, using an “ever vs never” categorization to assess initiation of chronic smoking. This is despite significant trait heritability ($h^2 = 0.554$) and genetic correlation with anxiety ($\rho_g = 0.550$). There has been greater success in the literature using smoking quantity or nicotine dependence phenotypes, which are genetically overlapping but not identical to smoking initiation [59]. However, these measures are unavailable in this sample. In a comprehensive meta-analysis of linkage studies looking at 3404 families, genome-wide significance was only observed with the phenotype of “maximum number of cigarettes per day”, on chromosome 20q13.12–13.32 [27]. Interestingly, in this metaanalysis, they failed to find evidence on linkage on chromosome 15q25, the location of the nicotinic acetylcholine receptor gene cluster which is a well-established hit for the phenotype of “cigarettes per day” from genome-wide association approaches [60].

4.3. Implications of findings

As a complex trait, addiction is likely to be highly polygenic, with both general and substance-specific components; the genetic loci identified to date only account for a small proportion of the variance in liability to addiction. Similarly, the genetic influences on anxiety traits remain poorly understood. By considering the relationships between addiction and anxiety, we aimed to reveal details of the genetic architecture underlying these comorbid traits. By demonstrating genetic correlations between addiction subtypes and anxiety, we
have shown that shared genetic etiology plays an important role in the high rates of comorbidity, although this does not exclude the existence of causal pathways between the two types of disorder. It still remains that addiction could manifest as a result of anxiety symptoms, or indeed vice versa. We suggest that a single generality is unlikely, heterogeneity between individuals and a pattern of multiple interacting pathways fits the diverse clinical picture more accurately. However, to begin to understand the biological pathways responsible for the shared genetic etiology of these two disorders, we must identify the specific genes involved.

Leveraging the increased statistical power of bivariate linkage analyses to identify the regions of the genome involved in this shared genetic etiology [33], we have highlighted potential pleiotropic regions of the genome, implicating both previously identified and novel chromosomal loci that may contribute risk for each these diagnoses. These regions point to candidates for further research into these disorders, and offer a potential starting point to begin to unpick the underlying neurobiology for each diagnosis and understand how they might be interconnected.

4.4. Characteristics of the sample

Our study examines a Mexican-American sample. Within the USA, it has been shown that the prevalence of addiction and psychiatric disorders in amongst Hispanics is generally lower than amongst non-Hispanic Caucasians; this is also true for black and Asians minorities [7,61]. However, there is variation within ethnic minority subgroups, according to interacting factors including country of origin, level of discrimination and acculturation [62–65]. Relating the prevalence of disorder within the sample to US national averages, we find that addiction phenotypes are more common in this sample, however, rates of anxiety are comparable to those reported in large epidemiological surveys [7,61].

In defining anxiety in this sample, we grouped all anxiety diagnoses along with PTSD and OCD together into a single category. This approach of grouping rather than splitting was taken for two reasons; first due to low numbers of cases for some diagnoses. Second, whilst this grouping does not capture known anxiety disorder-specific genetic influences, previous work shows that when all anxiety disorders (including PTSD and OCD) are considered, a common pathway model best describes the relationship between disorders, with most of the genetic effects being shared across disorders [20]. Additional epidemiological [66] and twin [21] research supports this approach. Whilst we relied upon DSM-IV criteria [38] to classify alcohol dependence, substance dependence and anxiety disorders, we note that in DSM-V [67] (published after the collection of this data), OCD and PTSD have been moved from the Anxiety Disorders chapter (to adjacent chapters of Obsessive-Compulsive and Related Disorders and Trauma and Stressor-Related Disorders) and changes have been made to criteria defining substance use disorders.

It is known that patients recruited into a study from a treatment setting often differ from the general population of affected individuals, particularly in terms of symptom severity and patterns of comorbidity [68]. By using a randomly ascertained extended pedigree sample, we have side-stepped these potential biases. Additionally, the extended pedigree design that we employ here offers increased power to detect quantitative trait loci over smaller family units.
in most circumstances [69], and while family studies typically do not directly estimate the
influence of environments shared by family members (as twin studies do), the inflation of
heritability estimates by these shared environmental influences are much less likely in
multigenerational families such as those included in this sample [70].

Given the contrasting prevalence by sex of addiction and anxiety, paired with overlapping
genetic liability, the manifestation of symptoms associated with this shared vulnerability
may differ by gender. It would be of interest to model genetic liability to these comorbidity
disorders in a sex-specific manner. However, this sample is not well suited to tackle the
issue, as sex-specific analyses would require breaking up the extended pedigree structure,
resulting in a substantial loss of statistical power and further, only autosomal chromosomes
are considered in this analysis.

5. Conclusions

In this study, we observe a number of significant quantitative trait loci that underlie the
genetic overlap of the addiction subtypes of alcohol dependence, drug dependence and
smoking with anxiety, within a randomly ascertained sample. The regions we identify show
some convergence with previous literature, but also highlight a number of novel genomic
loci involved in the comorbidity of these psychiatric traits.

Acknowledgments

Funding

Financial support for this study was provided by the National Institute of Mental Health grants MH078143 (PI:
D.C. Glahn), MH078111 (PI: J. Blangero), and MH083824 (PI: D.C. Glahn). SOLAR is supported by NIMH grant
MH059490 (J. Blangero).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.eurpsy.2016.03.004.

References

1. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-
ocurrence of substance use disorders and independent mood and anxiety disorders: results from the
National epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004; 61(8):

2. Compton WM, Thomas YF, Stinson FS, Grant BF, American medical association. Prevalence,
correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States:
results from the national epidemiologic survey on alcohol and related conditions. Arch Gen

3. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of
prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the
United States. Arch Gen Psychiatry. 2007; 64(7):830–42. [PubMed: 17606817]

alcohol dependence with other psychiatric disorders. Part I. Epidemiology of dual diagnosis


24. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper G, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008; 320(5875):539–43. [PubMed: 18369103]


44. Knowles EEM, Carless MA, de Almeida MAA, Curran JE, McKay DR, Sprooten E, et al. Genome-wide significant localization for working and spatial memory: identifying genes for


Fig. 1.
Significant univariate linkage signals. Alcohol dependence (Chr 16 LOD = 2.752 at 54cM); drug dependence (Chr 14 LOD = 3.322 at 41cM); smoking (Chr 4 LOD = 2.735 at 80cM); anxiety (Chr 12 LOD = 2.918 at 164cM).
Fig. 2.
Significant bivariate linkage signals. Alcohol dependence and anxiety (Chr 9 at 133cM, bivariate LOD = 3.054); drug dependence and anxiety (Chr 18 at 29cM, bivariate LOD = 3.425). Bivariate linkage shown in grey, overlaid on univariate signals.
### Table 1

Prevalence and heritability of addiction traits and anxiety.

<table>
<thead>
<tr>
<th>Trait</th>
<th>% cases (total n = 1284)</th>
<th>% female</th>
<th>Heritability</th>
<th>b²</th>
<th>P-value</th>
<th>SE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>23.4 (n = 300)</td>
<td>32.3</td>
<td>0.402</td>
<td>1.10E-05</td>
<td>0.110</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>10.6 (n = 136)</td>
<td>27.9</td>
<td>0.609</td>
<td>1.87E-05</td>
<td>0.165</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>33.9 (n = 435)</td>
<td>45.3</td>
<td>0.554</td>
<td>4.79E-13</td>
<td>0.095</td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>22.9 (n = 294)</td>
<td>78.2</td>
<td>0.287</td>
<td>3.96E-04</td>
<td>0.102</td>
<td></td>
</tr>
</tbody>
</table>
### Table 2

Addiction cases with comorbid anxiety.

<table>
<thead>
<tr>
<th></th>
<th>Percentage of cases with comorbid anxiety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol dependence</td>
<td>28.3%</td>
</tr>
<tr>
<td>(n = 85)</td>
<td></td>
</tr>
<tr>
<td>Drug dependence</td>
<td>38.2%</td>
</tr>
<tr>
<td>(n = 52)</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>22.5%</td>
</tr>
<tr>
<td>(n = 98)</td>
<td></td>
</tr>
<tr>
<td>Phenotypic correlation with anxiety</td>
<td>Genetic correlation with anxiety</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Alcohol dependence</td>
<td>0.281 (P=1.85E-06)</td>
</tr>
<tr>
<td>Drug dependence</td>
<td>0.412 (P=2.75E-09)</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.112 (P=4.15E-02)</td>
</tr>
</tbody>
</table>
Table 4
Best performing snps in association analysis. No snps pass peak-wide significance.

<table>
<thead>
<tr>
<th></th>
<th>Drug dependence</th>
<th>Anxiety</th>
<th>Alcohol dependence/anxiety</th>
<th>Drug dependence/anxiety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromosome</td>
<td>14</td>
<td>12</td>
<td>9</td>
<td>18</td>
</tr>
<tr>
<td>Size of linkage peak region (Mb)</td>
<td>8.46</td>
<td>2.66</td>
<td>4.98</td>
<td>1.20</td>
</tr>
<tr>
<td>No. of SNPs in peak</td>
<td>2728</td>
<td>1443</td>
<td>1643</td>
<td>552</td>
</tr>
<tr>
<td>Effective no. of SNPs in peak</td>
<td>1364.97</td>
<td>952.619</td>
<td>898.131</td>
<td>337.16</td>
</tr>
<tr>
<td>Peak-wide P-value threshold</td>
<td>3.76E-05</td>
<td>5.38E-05</td>
<td>5.71E-05</td>
<td>1.52E-04</td>
</tr>
<tr>
<td>Min P-value observed</td>
<td>2.62E-04</td>
<td>7.80E-05</td>
<td>1.30E-04</td>
<td>2.27E-03</td>
</tr>
<tr>
<td>Best SNP</td>
<td>rs17113722</td>
<td>rs10744424</td>
<td>rs10117151</td>
<td>rs11661395</td>
</tr>
<tr>
<td>Alleles</td>
<td>C/T</td>
<td>A/G</td>
<td>A/C</td>
<td>C/T</td>
</tr>
<tr>
<td>SNP MAF</td>
<td>0.052</td>
<td>0.117</td>
<td>0.433</td>
<td>0.478</td>
</tr>
<tr>
<td>Allele frequency in 1000 genomes MXL population</td>
<td>0.070</td>
<td>0.133</td>
<td>0.469</td>
<td>0.523</td>
</tr>
<tr>
<td>Allele frequency in 1000 genomes EUR population</td>
<td>0.082</td>
<td>0.156</td>
<td>0.625</td>
<td>0.416</td>
</tr>
<tr>
<td>Allele frequency in Alfred Pima Bajo population</td>
<td>0.020</td>
<td>0.000</td>
<td>0.120</td>
<td>Not available</td>
</tr>
<tr>
<td>Nearest gene</td>
<td>LRFN5 (nearest)</td>
<td>TMEM132D (intronic)</td>
<td>ASTN2 (nearest)</td>
<td>RAB12 (nearest)</td>
</tr>
</tbody>
</table>